Drugs known to repress HIF-1α expression indirectly, such as mTOR inhibitors, can also be used as adjuvant therapy for cancer because it has been shown in preclinical models of HCC that such treatment can suppress tumor growth. Here, HIF1A is linked to hepatocellular carcinoma.